Cerevel Therapeutics, Inc.

Cerevel Therapeutics, Inc. , based in the US, develops innovative therapies targeting neurological and psychiatric disorders, aiming to improve treatment outcomes for patients. Founded in 2018 and headquartered in Cambridge, US, Cerevel Therapeutics focuses on creating therapies for conditions like schizophrenia and Parkinson's disease. The company recently transitioned to being a part of AbbVie and has successfully raised USD 8,700 mn through a TRADE SALE in October 2023, with a total of 7 deals since its inception.

The CEO of the firm is Ron Renaud. Cerevel, now part of AbbVie, focuses on developing transformative therapies aimed at addressing neurological and psychiatric disorders. Their primary product offerings include innovative treatments that enhance the standards of care for conditions such as schizophrenia, epilepsy, and Parkinson's disease. The company serves a diverse clientele, including healthcare providers, hospitals, and pharmaceutical distributors, primarily in North America and select countries in Europe and Asia.

The products are aimed at both healthcare professionals who prescribe them and patients who directly benefit from their therapeutic effects. Cerevel generates revenue through partnerships and collaborations with healthcare organizations and pharmaceutical distributors, focusing on delivering its flagship therapies to the market. The transaction structure typically involves agreements with healthcare providers for the supply of their innovative treatment solutions, often transitioning from direct sales to broader distribution channels as market demand increases. Pricing strategies are established based on the therapeutic value provided by their medications, ensuring they remain competitive while addressing the needs of their users.

For the most recent fiscal year ending in 2023, the company reported an EBITDA of USD -461. 34 mn. In October 2023, Cerevel Therapeutics, Inc. raised approximately USD 450 mn in a public offering, selling 19.

728 million shares at USD 22. 81 per share on the Nasdaq Capital Market. The company has plans to utilize the recent funding to support the development of new products targeting neurological and psychiatric conditions. Additionally, Cerevel is looking to expand its market presence in North America and select European and Asian countries by the end of 2024, leveraging their innovative treatment solutions to meet increasing market demands.